Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical Product Development (PPD), a global contract research organization that provides drug discovery, development and lifecycle management services, has reported total net revenue of $383.2m for the first quarter ended 31 March 2011, an increase of 10.5%, compared to $346.77m for the same period in 2010.
Subscribe to our email newsletter
PPD has posted a net income of $37.37m, or $0.32 per diluted share, compared to $17.2m, or $0.14 per diluted share, for the same period in 2010.
For the first quarter of 2011, the company’s operating income was $52.45m, compared to $27.68m for the same period in 2010.
PPD CEO David Grange said clinical development services segment margins remained strong for the quarter, while laboratory services segment results were impacted by higher than normal project cancellations and postponements and increased investment in research and development to support the future growth of drug discovery services business.